Targeting a gene linked to cardiovascular disease shows therapeutic promise.
This is a preview of subscription content, log in via an institution to check access.
References
Rothgangl, T. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-00933-4 (2021).
Musunuru, K. et al. Nature 593, 429–434 (2021).
Zhang, D. W. et al. J. Biol. Chem. 282, 18602–18612 (2007).
Abifadel, M. et al. Nat. Genet. 34, 154–156 (2003).
Cohen, J. et al. Nat. Genet. 37, 161–165 (2005).
First in vivo human genome editing trial. Nat. Biotechnol. 36, 5 (2018).
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Nat. Biotechnol. 38, 824–844 (2020).
Jin, S. et al. Science 364, 292–295 (2019).
Zuo, E. et al. Science 364, 289–292 (2019).
Chadwick, A. C., Wang, X. & Musunuru, K. Arterioscler. Thromb. Vasc. Biol. 37, 1741–1747 (2017).
Gaudelli, N. M. et al. Nat. Biotechnol. 38, 892–900 (2020).
Hanlon, K. S. et al. Nat. Commun. 10, 4439 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
van Kampen, S.J., van Rooij, E. CRISPR base editing lowers cholesterol in monkeys. Nat Biotechnol 39, 920–921 (2021). https://doi.org/10.1038/s41587-021-00975-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-00975-8
- Springer Nature America, Inc.
This article is cited by
-
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
Current Atherosclerosis Reports (2022)